CoreCap Advisors’s Cartesian Therapeutics RNAC Stock Holding History

CoreCap Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1	Closed	–	–	3166
2025 Q1	$0	Hold	1	–	–	﹤0.01%	3274
2024 Q4	$0	Hold	1	–	–	﹤0.01%	2960
2024 Q3	$0	Buy	+1	New	+$16	﹤0.01%	2724

Other funds holding RNAC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CoreCap Advisors's RNAC Position: Q2 2025 in Review

CoreCap Advisors sold out of Cartesian Therapeutics (RNAC) in Q2 2025, closing a stake of 1 share.

CoreCap Advisors first reported a position in RNAC in Q3 2024 and held it in 3 quarters. The position peaked at $0 in Q1 2025. 66 funds tracked by Wall St. Rank hold RNAC as of Q2 2025.

CoreCap Advisors reported no remaining Cartesian Therapeutics position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 1 Cartesian Therapeutics share in Q2 2025.
CoreCap Advisors first reported a position in Cartesian Therapeutics in Q3 2024 and held it in 3 quarters.
CoreCap Advisors's Cartesian Therapeutics position peaked at $0 in Q1 2025.
66 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.